News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
7/7/2009 10:49:20 AM
Glasgow, U.K., 6th July 2009 – Bio-Images Research Ltd. today announced that Professor
Howard Stevens, Chairman, will speak to members of the pharmaceutical and biotechnology
industries attending the 36th Annual Meeting and Exposition of the Controlled Release
Society, to be held in Copenhagen, Denmark, 18th – 22nd July 2009.
Professor Steven’s Soapbox Session at the conference on Sunday 19th July, entitled
“Breaking Up in the GI Tract”, will focus on Bio-Images more recent endeavours in
characterising erosion behaviour of matrix tablets using gamma scintigraphy and pulmonary
models for mucociliary clearance.
Gamma scintigraphy is a well established non-invasive imaging technique with numerous
applications in the field of drug delivery. The technique is used to assess the in vivo
behaviour of novel formulations, and can also be combined with pharmacokinetics.
Information from these studies will assist development decision making, including the
development of new formulations as well as re-formulation of existing products, and
marketing. Bio-Images have particular expertise in solving concerns with ‘problem’
formulations, such as dose dumping and food effects.
Representatives from Bio-Images clinical research team will also attend the 2009 Controlled
Release Society (CRS) Annual Meeting, where the company are exhibiting at booth #307.
Bio-Images Research Ltd. was founded in October 2000 as a spin out company from the
University of Strathclyde. Bio-Images undertakes early phase clinical studies in volunteers
and patient groups, specialising in gamma scintigraphy. Non-invasive scintigraphic imaging is
used to monitor the behaviour of oral, nasal, pulmonary and ophthalmic formulations. All
studies are fully compliant with ICH-GCP guidelines with all clinical trial supplies
manufactured in a GMP facility.